These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25249588)

  • 1. Growth factor use in medication-induced hematologic toxicity.
    Miller RC; Steinbach A
    J Pharm Pract; 2014 Oct; 27(5):453-60. PubMed ID: 25249588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preventing and treating hematologic complications of anticancer chemotherapy: update on hematopoietic growth factors].
    Spaëth D; Geoffrois L; Conroy T
    Bull Cancer; 2000 Jan; 87(1):93-6. PubMed ID: 10673637
    [No Abstract]   [Full Text] [Related]  

  • 4. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prophylactic use of hematopoietic growth factors (G-CSF, GM-CSF) in prevention of chemotherapy-induced myelosuppression in children].
    Osińska-Królak M; Kurylak A; Wysocki M; Kurylak D; Kindracka A; Balcar-Boroń A
    Wiad Lek; 2003; 56(3-4):152-6. PubMed ID: 12923962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia.
    Kurzrock R
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):9-11. PubMed ID: 11033833
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced myelosuppression : diagnosis and management.
    Carey PJ
    Drug Saf; 2003; 26(10):691-706. PubMed ID: 12862504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
    N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High dose chemotherapy in malignant gliomas using autologous bone marrow transplantation and GM-CSF: granulocyte-macrophage colony stimulating factors].
    Yamashita J; Kawamura T; Shoin K
    No Shinkei Geka; 1990 Apr; 18(4):329-38. PubMed ID: 2197571
    [No Abstract]   [Full Text] [Related]  

  • 13. [The strategy for chemotherapy-induced myelosuppression].
    Hangaishi A
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1777-81. PubMed ID: 22083184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.
    Saloustros E; Tryfonidis K; Georgoulias V
    Expert Opin Pharmacother; 2011 Apr; 12(6):851-63. PubMed ID: 21254862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Leukopenia and thrombopenia induced by chemotherapy].
    Nieweg R; van Rijswijk R
    TVZ; 1992 Jan; (2):53-5. PubMed ID: 1540322
    [No Abstract]   [Full Text] [Related]  

  • 17. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose reductions and delays: limitations of myelosuppressive chemotherapy.
    Cairo MS
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):21-31. PubMed ID: 11033835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy.
    Blumenthal RD; Lew W; Juweid M; Alisauskas R; Ying Z; Goldenberg DM
    Cancer; 2000 Jan; 88(2):333-43. PubMed ID: 10640965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic factors for febrile neutropenia].
    Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
    Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.